DK1047428T3 - Anvendelse af morpholinol til behandlingen af seksualforstyrrelser - Google Patents

Anvendelse af morpholinol til behandlingen af seksualforstyrrelser

Info

Publication number
DK1047428T3
DK1047428T3 DK99903200T DK99903200T DK1047428T3 DK 1047428 T3 DK1047428 T3 DK 1047428T3 DK 99903200 T DK99903200 T DK 99903200T DK 99903200 T DK99903200 T DK 99903200T DK 1047428 T3 DK1047428 T3 DK 1047428T3
Authority
DK
Denmark
Prior art keywords
morpholinol
treatment
sexual disorders
sexual
disorders
Prior art date
Application number
DK99903200T
Other languages
Danish (da)
English (en)
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partridge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1047428T3 publication Critical patent/DK1047428T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99903200T 1998-01-21 1999-01-20 Anvendelse af morpholinol til behandlingen af seksualforstyrrelser DK1047428T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (fr) 1998-01-21 1999-01-20 Morpholinol pharmaceutiquement actif

Publications (1)

Publication Number Publication Date
DK1047428T3 true DK1047428T3 (da) 2007-10-08

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99903200T DK1047428T3 (da) 1998-01-21 1999-01-20 Anvendelse af morpholinol til behandlingen af seksualforstyrrelser

Country Status (30)

Country Link
US (2) US6274579B1 (fr)
EP (2) EP1047428B1 (fr)
JP (1) JP2002501025A (fr)
KR (1) KR100568063B1 (fr)
CN (2) CN1203858C (fr)
AP (1) AP1229A (fr)
AT (1) ATE365042T1 (fr)
AU (1) AU755536B2 (fr)
BR (1) BR9907203A (fr)
CA (1) CA2318268A1 (fr)
CY (1) CY1106828T1 (fr)
DE (1) DE69936335T2 (fr)
DK (1) DK1047428T3 (fr)
EA (1) EA002410B1 (fr)
EE (1) EE04452B1 (fr)
ES (1) ES2288012T3 (fr)
HR (2) HRP20000494B1 (fr)
HU (1) HUP0100900A3 (fr)
ID (1) ID26334A (fr)
IL (2) IL161942A0 (fr)
IS (1) IS2494B (fr)
NO (2) NO326878B1 (fr)
NZ (3) NZ529316A (fr)
PL (1) PL193622B1 (fr)
PT (1) PT1047428E (fr)
SG (1) SG115489A1 (fr)
SK (1) SK10912000A3 (fr)
TR (1) TR200002126T2 (fr)
WO (1) WO1999037305A1 (fr)
YU (1) YU67102A (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
CA2318920A1 (fr) 1998-01-29 1999-08-05 James W. Young Utilisations pharmaceutiques de (-)-bupropion optiquement pur
US6458374B1 (en) 1998-01-29 2002-10-01 Sepracor, Inc. Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
JP2003511410A (ja) * 1999-10-13 2003-03-25 グラクソ グループ リミテッド 肥満症の治療のためのモルホリノール誘導体
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2365428C (fr) * 2000-12-21 2008-10-21 Brasscorp Limited Methode pour produire une source de lumiere ultraviolette ou proche de l'ultraviolet destinee a une inspection ou un essai non destructif
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
EP2301537A1 (fr) * 2002-05-17 2011-03-30 Duke University Zonisamide pour le traitement de l'obésité
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7384941B2 (en) * 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
CN1784221B (zh) * 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
WO2005042503A1 (fr) * 2003-10-27 2005-05-12 Smithkline Beecham Corporation Procede de resolution cinetique dynamique catalysee par des enzymes permettant de preparer du (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, des sels et des solvates de ce dernier
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
EP1734955A2 (fr) 2004-01-13 2006-12-27 Duke University Compositions anticonvulsives, medicament antipsychotique et leurs methodes d'utilisation permettant d'influer sur la perte de poids
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
WO2007079470A2 (fr) 2006-01-03 2007-07-12 Algebra, Inc. Composes therapeutiques amine-arylsulfonamide conjugues
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
CA2758774C (fr) 2009-04-15 2015-02-03 Research Triangle Institute Inhibiteurs de la recapture des monoamines
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
AU2011255276B2 (en) 2010-05-21 2016-09-22 Research Triangle Institute Phenylmorpholines and analogues thereof
ES2546492T3 (es) 2010-05-21 2015-09-24 Research Triangle Institute Derivados de 1-fenilmorfolina como análogos de hidroxibupropion para tratar drogodependencia
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-(2-芳基吗啉-4-基)乙酯作为制备抗抑郁药物的应用
CA2875056C (fr) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methodes de traitement de la surcharge ponderale et de l'obesite
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
US6274579B1 (en) 2001-08-14
PL193622B1 (pl) 2007-02-28
CN1203858C (zh) 2005-06-01
NO20003721L (no) 2000-09-19
WO1999037305A1 (fr) 1999-07-29
EP1047428A4 (fr) 2001-12-19
ES2288012T3 (es) 2007-12-16
ID26334A (id) 2000-12-14
IS2494B (is) 2009-02-15
PL342012A1 (en) 2001-05-07
CY1106828T1 (el) 2012-05-23
HRP20051024A2 (hr) 2006-04-30
NZ520349A (en) 2004-02-27
DE69936335T2 (de) 2008-02-28
US20020019396A1 (en) 2002-02-14
IS5568A (is) 2000-07-20
IL161942A0 (en) 2005-11-20
NO20003721D0 (no) 2000-07-20
US6391875B2 (en) 2002-05-21
NZ529316A (en) 2004-05-28
EA200000691A1 (ru) 2001-04-23
KR100568063B1 (ko) 2006-04-07
AP1229A (en) 2003-12-04
EP1047428A1 (fr) 2000-11-02
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
HUP0100900A3 (en) 2002-08-28
HUP0100900A2 (hu) 2002-05-29
PT1047428E (pt) 2007-09-07
EE04452B1 (et) 2005-04-15
HRP20000494A2 (en) 2000-12-31
SG115489A1 (en) 2005-10-28
KR20010034285A (ko) 2001-04-25
AU2328099A (en) 1999-08-09
JP2002501025A (ja) 2002-01-15
EP1829544A1 (fr) 2007-09-05
EA002410B1 (ru) 2002-04-25
CN1255389C (zh) 2006-05-10
EP1047428B1 (fr) 2007-06-20
DE69936335D1 (de) 2007-08-02
NZ505809A (en) 2002-09-27
HRP20000494B1 (en) 2009-02-28
NO326878B1 (no) 2009-03-09
CN1294513A (zh) 2001-05-09
AU755536B2 (en) 2002-12-12
TR200002126T2 (tr) 2000-12-21
YU67102A (sh) 2004-12-31
EE200000438A (et) 2001-12-17
SK10912000A3 (sk) 2001-04-09
BR9907203A (pt) 2000-10-17
ATE365042T1 (de) 2007-07-15
AP2000001869A0 (en) 2000-09-30
NO20083529L (no) 2000-09-19
CA2318268A1 (fr) 1999-07-29

Similar Documents

Publication Publication Date Title
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK0967214T3 (da) Intranasale formuleringer til behandling af seksuelle forstyrrelser
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
DK0966436T3 (da) Arylsulfonamider og analoger deraf og anvendelse deraf til behandling af neurodegenerative lidelser
DK1083889T3 (da) Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
DK1223927T3 (da) Anvendelse af retigabin til behandling af neuropatiske smerter
DK1604680T3 (da) Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
DE60020327D1 (de) Wasserbehandlungsvorrichtung
IS5921A (is) Staðgengnar Bensópýrahliðstæður til notkunar við meðhöndlun á bólgu
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
DE69921571D1 (de) Massagegerät
IS6137A (is) Meðhöndlun á hugsýkistruflunum
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
DK0928183T3 (da) Anvendelse af 1-hydroxy-2-pyridoner til behandling af seborrhoisk dermatitis
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
NO20010390D0 (no) Behandling av angstsykdommer
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
EE200200670A (et) S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks
DK1011678T3 (da) Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
IS5324A (is) (S) 2-Metýlamínó-2-fenýl-n-bútýl 3,4,5-trímetoxý-bensóat, notkun þess til meðferðar á langvinnum sársauka